NEW YORK — Pfizer on Tuesday revealed its experimental COVID-19 pill can cut the risk of hospitalization or death by 89% in high-risk patients, while separate studies suggest the drug also retains its efficacy against the fast-spreading omicron variant. The New York-based pharmaceutical company noted the anti-viral treatment proved most effective when given to high-risk adults within several days of their first symptoms. Of the 697 study participants who received the drug within the first three days, no deaths were reported and only five people were hospitalized, Pfizer said in a press release…

Read More